Evidence map›Paper›PMID 37012340›Full record

ArticleScientific reports2023

Investigation of time profile of FEV

Masaru Suzuki, Isao Matsumoto, Masato Ishida, Yoshiharu Horie, Hideyuki Ban, Wataru Takeuchi, Shunki Nakagawa, Tohru Nakagawa, Tetsuhisa Kitamura, Shigeo Muro

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Masaru SuzukiDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Isao MatsumotoDepartment of Respiratory, Inflammation, and Autoimmune, Medical, AstraZeneca K.K., Osaka, Japan. isao.matsumoto1@astrazeneca.com.
Masato IshidaDepartment of Respiratory, Inflammation, and Autoimmune, Medical, AstraZeneca K.K., Osaka, Japan.
Yoshiharu HorieDepartment of Data Science, Medical, AstraZeneca K.K., Osaka, Japan.
Hideyuki BanHealthcare IT Research Department, Center for Digital Services-Healthcare, Hitachi, Ltd. Research and Development Group, Tokyo, Japan.
Wataru TakeuchiHealthcare IT Research Department, Center for Digital Services-Healthcare, Hitachi, Ltd. Research and Development Group, Tokyo, Japan.
Shunki NakagawaHealthcare IT Research Department, Center for Digital Services-Healthcare, Hitachi, Ltd. Research and Development Group, Tokyo, Japan.
Tohru NakagawaHitachi Health Care Center, Hitachi, Ltd., Ibaraki, Japan.
Tetsuhisa KitamuraDivision of Environmental Medicine and Population Sciences, Department of Social and Environmental Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
Shigeo MuroDepartment of Respiratory Medicine, Nara Medical University, Nara, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study compared the time profile of FEV

Indexed as

Pulmonary Disease, Chronic ObstructiveForced Expiratory VolumeHumansJapanLungRespiratory Function TestsRetrospective Studies

Identifiers

PMID37012340
PMCPMC10070435

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.